Aprea Therapeutics, Inc. SEC filings APRE

Aprea Therapeutics, Inc. has 446 filings in SEC EDGAR's recent list, going back to Jul 12, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 30, 2026 Dec 31, 2025
10-K Annual report Mar 16, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 22, 2025 Dec 31, 2024
10-K Annual report Mar 25, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 25, 2024 Dec 31, 2023
10-K Annual report Mar 26, 2024 Dec 31, 2023
ARS Annual report to shareholders Jul 11, 2023 Dec 31, 2022
10-K/A Amended annual report Apr 28, 2023 Dec 31, 2022
10-K Annual report Mar 30, 2023 Dec 31, 2022
10-K/A Amended annual report May 2, 2022 Dec 31, 2021
10-K Annual report Mar 15, 2022 Dec 31, 2021
10-K Annual report Mar 16, 2021 Dec 31, 2020
10-K Annual report Mar 27, 2020 Dec 31, 2019

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
APRE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Doylestown, PA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1781983

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.